Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Amniotic Membrane Companies

ID: MRFR/HC/4190-CR
200 Pages
Vikita Thakur
Last Updated: February 16, 2025
Amniotic membrane is a tissue that lines the innermost layer of the placenta and is used for various medical and surgical applications due to its regenerative and anti-inflammatory properties. Several companies specialize in processing and distributing amniotic membrane products for clinical use.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Amniotic Membrane Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)16.26%
2024 Market Size$ 1,453.28 Million
2025 Market Size$ 1,689.61 Million
2035 Market Size$ 7,623.68 Million
Key Players
Amnion Life
MiMedx Group
Organogenesis
Tissue Regenix
Smith & Nephew
Allergan
Trends
  • Rising Applications in Regenerative Medicine
  • Technological Advancements in Processing Techniques
  • Increased Focus on Chronic Wound Management
Opportunities
  • Market Growth Projections
  • Growing Geriatric Population
  • Supportive Regulatory Framework
Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Amniotic Membrane Market

<a href=Amniotic Membrane Key Companies" width="600" height="300">*Disclaimer: List of key companies in no particular orderLatest Amniotic Membrane Companies Update
  • July 2023: Verséa Ophthalmics, LLC, a Tampa, Florida-based company that specializes in providing comprehensive ocular point-of-care diagnostic and therapeutic interventions, and Celularity Inc., a biotechnology firm developing placental-derived allogeneic cell treatments and biomaterial products, today announced that the two companies have signed into a special U.S. commercialization consensus in which Verséa Ophthalmics will distribute Celularity's BIOVANCE® and BIOVANCE® 3L Ocular products to assist with the treatment of ocular surface disease and ocular surgical uses. Severe ocular surface disease can be handled with BIOVANCE® 3L Ocular, an acellular solution made of three layers of amniotic membrane. The purpose of BIOVANCE® 3L Ocular as a barrier membrane is to maintain tissue plane boundaries and safeguard the underlying tissue.
  • Aug 2023: The Smith & Nephew UK Pensions Fund and Rothesay have finalized a £260 million buy-in agreement. Following earlier deals between the two in 2013, 2017, and 2022, the scheme is now underwritten by medical technology company Smith & Nephew UK. As a result, all scheme participants are now covered with Rothesay. This buy-in transaction is the most recent in a series of buy-in deals that Rothesay has announced this year, including a £1.4 billion buy-in with the Safeway Pension Scheme that guaranteed benefits to over 22,500 members, a £762 million agreement with Morrisons, and a £160 million buy-in with the Repsol Sinopec Pension and Life Scheme.List of Amniotic membrane Key companies in the market

  • Tissue-Tech Inc. (US)

  • Applied Biologics (US)

  • LifeLike BioTissue (US)

  • Celularity Inc, (U.S)

  • Labtician Ophthalmics Inc. (Canada)

  • Smith+Nephew (UK)

  • Stryker (US)

  • WWW.SURGILOGIX.COM. (US)

  • Integra LifeSciences (U.S)

  • MiMedx (US)

  • Skye Biologics Holdings LLC (US)

  • Amniox Medical Inc (U.S)

  • Human Regenerative Technologies LLC (US)

  • Katena Products Inc (US)

  • Amnio Technology, LLC (US)

Related Reports

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035